Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label dose-finding study of KRN23 in children with XLH
NL-OMON45206Phase 2Active, not recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of burosumab in X-linked hypophosphataemia (XLH) (6 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoints: Serum phosphorus, Serum 1,25-dihydroxyvitamin D and 13 more. Started Oct 2014; status: active, not recruiting.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphataemia (XLH)
Beyond the preview
Go deeper on NL-OMON45206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45206.